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Open access under CC BYA live, attenuated vaccine is currently the only viable option to control of CBPP in Africa. It has been sug-
gested that simple modiﬁcations to current vaccines and protocols might improve efﬁcacy in the ﬁeld. In
this report we compared the current vaccine formulation with a buffered preparation that maintains
Mycoplasma viability at ambient temperature for a longer time. Groups of animals were vaccinated with
the two formulations and compared with non vaccinated groups. Half of the animals in each group were
challenged 3 months post vaccination, the other half after 16 months. Protection levels were measured
using the pathology index, calculated from post mortem scores of lesions from animals killed during
the course of clinical disease. In the challenge at 3 months post vaccination, the protection levels were
52% and 77% for the modiﬁed and current vaccine preparations, respectively. At 16 months post vaccina-
tion, the protection levels were 56% and 62% for the modiﬁed and current vaccine preparations, respec-
tively. These ﬁndings indicate that there are no differences in protection levels between the two vaccines.
Because of its longer half life after reconstitution, the modiﬁed vaccine might be preferred in ﬁeld situ-
ations where the reconstituted vaccine is likely not to be administered immediately.
 2011 Elsevier Ltd. Open access under CC BY license.1. Introduction
Contagious bovine pleuropneumonia (CBPP) is an important
disease of cattle in Africa, causing an annual economic loss esti-
mated at US$ 2 billion (Masiga et al., 1998) due mainly to mortal-
ities. It also affects local and international trade due to animal
movement restrictions, and further losses may be incurred during
eradication campaigns, as evidenced by Botswana in 1995 (Amanfu
et al., 1998).
In Africa, the disease spread alarmingly during the 1990s, affect-
ing several countries previously free from the disease (March et al.,
2000) and causing greater losses in cattle than any other disease
(OIE, 1995). The factors contributing to this resurgence were
thought to include the collapse of veterinary services (Provost,
1996), increased and unrestricted cattle movements as a result of
drought, war, or civil strife (Windsor and Wood, 1998), and poor
vaccine efﬁcacy (Rweyemamu et al., 1995; Thiaucourt et al.,
2000). According to Roeder and Rweyemamu (1995), between-zoneesearch Institute, Veterinary
. Nkando).
 license.or -country contagion was basically related to cattle movements
caused by trade, transhumance and social plight.
The low efﬁcacy of the current live vaccine is a big problem for
Africa, where CBPP is controlled mainly through vaccination, sup-
plemented only by quarantine and restriction of animal move-
ment. Policies like control through slaughter of cattle are difﬁcult
to implement in Africa for a variety of reasons, including the cost
of compensation.
While vaccine coverage and protection rates of 80–90% are the
target for vaccination campaigns to maintain a disease free status,
current CBPP vaccines give protection rates as low as 30–60% after
primary vaccination (Wesonga and Thiaucourt, 2000). This sug-
gests that, even with high levels of cover, effective control of the
disease will not be achieved with the current vaccine. Since Myco-
plasma mycoides subspecies mycoides small colony (MmmSC), the
causative agent of CBPP, is pH sensitive (March et al., 2002), it
has been speculated that a loss of viability occurs in the time be-
tween reconstitution and administration of the vaccine, thus con-
tributing to the low level of protection. Modiﬁcations to the
media used in growing the organism have been found to result
in greater viability, and changes in the diluent used for reconstitu-
tion resulted in prolongation of viability under laboratory
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uate the usefulness of this modiﬁcation in vaccine preparations, an
experimental trial was conducted to compare the efﬁcacy of the
vaccine grown in buffered medium with the current vaccine prep-
aration. Vaccinated cattle were challenged at 3 or 16 months post
vaccination and compared with non-vaccinated cattle.Table 1
Ultimate groupings of experimental cattle at the time of challenge, and number of
animals that provided data.
Group Number of animals Immunizing inoculum Challenge
1 15 Standard 3 months
2 14 Modiﬁed 3 months
3 15 PBS 3 months
4 15 Standard 16 months
5 14 Modiﬁed 16 months
6 15 PBS 16 months2. Materials and methods
2.1. Animals
Ninety male cattle (Bos indicus or East African Zebu) aged
2–3 years, were purchased from the Kakamega district of the Wes-
tern Province, Kenya. The area is historically known to be free from
CBPP and away from stock routes associated with CBPP-infected
cattle. Prior to purchase, they were ear-tagged, bled and conﬁrmed
negative for CBPP antibodies using the slide agglutination test
(SAT), the complement ﬁxation test (CFT; Campbell and Turner,
1953) and the competitive enzyme linked immunosorbent assay
test (cELISA; CIRAD-EMVT, France; Le Goff and Thiaucourt, 1998).
They were transported to the experimental station (Veterinary Re-
search Centre, Muguga – Kenya Agricultural Research Institute,
KARI, Central Province), where they were administered with Nilzan
plus cobalt (Cooper, Nairobi, Kenya) for helminth control and vac-
cinated against Foot-and-Mouth disease (FMD), lumpy skin disease
(LSD), blackleg and anthrax over 3 months, during which they were
grazed during the day and conﬁned in a paddock at night. The ani-
mals were handled according to KARI Animal Welfare Committee
regulations.
2.2. Vaccine production
Standard and the modiﬁed freeze-dried batches of the T144 vac-
cine strain of MmmSC (batch numbers 02/06 and 03/06, respec-
tively) were obtained from KARI-Veterinary Vaccine Production
Centre, prepared in accordance with standard operating proce-
dures. The Mycoplasma for the vaccines were grown from a vali-
dated stock of T1/44, used for commercial production. The
standard vaccine was produced in Gourlay medium as described
(Litamoi et al., 1996). The modiﬁed vaccine was prepared by grow-
ing the Mycoplasma in a HEPES-buffered system in conjunction
with Gourlay medium as described (Waite and March, 2001).
Titration ofMycoplasma in the vaccine preparations was carried
out by the standard method of microtitration and color change and
calculation of the titre by using the Spearman–Karber formula
(Litamoi et al., 1996). Vaccines were reconstituted in a volume of
phosphate buffered saline (PBS) (for the modiﬁed vaccine) or nor-
mal saline (for the standard vaccine) provided with the vaccines, so
that the ﬁnal titre of Mycoplasma was 107/ml.
2.3. Experimental design
The 90 cattle were divided into three randomized cohorts of 30,
each of which was vaccinated with the standard vaccine, modiﬁed
vaccine or diluent alone (sterile phosphate buffered saline; PBS). A
blind randomization protocol was used. Animals were vaccinated
with 0.5 ml as follows: for the standard vaccine, the vial was recon-
stituted with 7.5 ml of normal saline to make 15 doses of 0.5 ml
each. The modiﬁed vaccine with an initial high Mycoplasma titre
was reconstituted with 50 ml of PBS to make 100 doses of 0.5 ml
each. The diluents in which the vaccines were reconstituted were
placed on ice during reconstitution. This was carried out at the
crush site where the animals were to be vaccinated.
Each of the 90 animals was subcutaneously inoculated with
0.5 ml of the standard vaccine, the modiﬁed vaccine or PBS at thecaudal aspect of the tail or the tail-tip (Turner and Trethewie,
1961). After vaccination, the three cohorts were grazed and housed
separately (between 200 and 500 m apart) for a period of 30 days
after which they were managed as a single group. The thickness
of the tail-tip (circumference of tail around the last coccyx) was
measured daily in each animal for 30 days after inoculation to as-
sess the occurrence of post-vaccinal reactions. Rectal temperatures
were taken daily, between 08.00 and 10.00, with temperatures of
39.5 C and above considered indicative of fever. Up to 3 months
post vaccination, the animals were bled weekly for preparation
of serum samples on which CFT and cELISA tests were carried
out. After 3 months, half of the cattle from each cohort were ran-
domly selected and treated as groups 1–6 (Table 1). Groups 1, 2
and 3 were challenged at 3 months, and those in groups 4, 5 and
6 were bled monthly thereafter until challenge at 16 months;
weekly bleeding was resumed after challenge to monitor infection
parameters.2.4. Challenge and clinical examination
Challenge was carried out by endoscopic intubation using path-
ogenic MmmSC cultures obtained from the Kenyan B237 isolate of
MmmSC. Brieﬂy, each animal was intubatedwith a ﬁbre-optic bron-
choscope (VFS-2A, Swiss Precision, USA) through which 60 ml of
MmmSC culture containing 3  108 colony forming units (cfu) of
MmmSC was introduced into the distal trachea, followed sequen-
tially by 15 ml of 1.5% low temperature melting agar (36 C) sus-
pended in distilled water and 35 ml of PBS at 36 C. The animals
were observed daily for clinical signs for the period during which
they were fed outdoors (09.00–15.30).2.5. Necropsy and sample collection
Cattle showing fever for 10 days were euthanized on humane
grounds, while those that did not were killed at 45 days post chal-
lenge. The animals were stunned and then exsanguinated before a
full post-mortem examination was carried out.2.6. Lesion scoring
The size of lung lesions (diameter in cm) was recorded and lung
pathology scored according to the system proposed by Hudson and
Turner (1963), in which the score is a combination of the size of the
lesion and the isolation of theMmmSC from tissues. We also calcu-
lated a score based solely on lung lesions as follows: grossly nor-
mal lungs, 0; ﬁbrosis or evidence of disease remission, 1;
presence of adhesions or consolidation, 2. Where sequestra were
present, they were scored on the basis of size: less than 5 cm, 3;
between 5 and 10 cm, 4; between 10 and 20 cm, 5; over 20 cm,
6. Protection rate (deﬁned as the percentage reduction in lung
pathology brought about by vaccination) was calculated from the
lesion scores of control and vaccinated animals according to
Hudson and Turner (1963), using the formula (NV  V)  100/NV,
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2.7. CFT and cELISA tests
The serum samples were tested using the cELISA test kit devel-
oped by CIRAD-EMVT, France, as described by the manufacturers.
The optical density (OD) was measured at 450 nm with a plate
reader (PR 2100, Sanoﬁ, Pasteur diagnostic, US) and the percentage
inhibition (PI) value for each serum sample calculated. A cut-off
point of 50% inhibition was used to determine positive and nega-
tive samples, with a range between 45% and 55% being considered
doubtful.
CFT was performed essentially according to the method of
Campbell and Turner (1953). Brieﬂy, the test employed commer-
cially prepared complement and hemolysin (Biomereau), and re-
sults were read after overnight incubation at 4 C. Samples with a
reading of 3 or 4 in a 1:10 dilution were re-titrated to obtain the
end point titre. A reading of 2 or 1 at the 1:10 dilution was consid-
ered negative while readings of 4, 3 and 2 were considered
positive.
2.8. Statistical analysis
On vaccine titration, analysis of variance (ANOVA) was used to
determine if there were differences in titres between the two vac-
cines at different temperatures and periods. GenStat statistical
software (9th edition) was used in the analysis. The difference be-
tween means in the variables (vaccine, temperature and time) was
analyzed.
Comparative analysis of the changes in tail-tip circumferences
and rectal temperatures between animals vaccinated with the
standard vaccine, the modiﬁed vaccine, and the controls was per-
formed using ANOVA. Pathology scores were evaluated to deter-
mine if there was a difference in protection afforded by the two
vaccines. Differences between mean pathology scores in the three
groups (vaccinates and controls) were also analyzed using ANOVA.
To evaluate differences between the antibody response (as re-
vealed by CFT and cELISA tests) induced by the two vaccines, a
comparison of the proportions of the animals (vaccinates and con-
trols) that responded was performed using Chi-square (v2) test.3. Results
3.1. Post vaccination responses
Daily mean tail-tip circumferences (in cm) of control (injection
with PBS) and vaccinated cattle over 30 days post vaccination wereTable 2
Infection and pathology parameters after challenge of vaccinated and non-vaccinated grou
Challenge post vaccination 3 months
Vaccination group Standard Modiﬁed
Number of cattle 15 14
Average number of fever days post challenge 1.5 3.1
% Euthanised 20% 29%
% With Mycoplasma isolated 20% 36%
% With lesions 60% 43%
Average lesion scorea 2.7 ± 2.8 2.7 ± 2.6
Average Hudson scoreb 1.9 ± 2.2 4.0 ± 5.5
% Seroconverted CFT 53% 36%
% Seroconverted cELISA 64% 46%
Vaccine efﬁcacy 77% 52%
a Lesion score calculated from the size of lung lesions.
b Lesion score calculated as a combination of lung lesion and tissue isolation of Mycocollected. The observed changes arose either from circumscribed
swellings or a bulb of variable diameter at the site of inoculation.
The circumferences in individual animals differed from 3.5 cm for
control animals to 5.1 cm for severely affected animals and varied
between 3 and 21 days post-inoculation in both vaccinated groups.
In 11 animals inoculated with the standard vaccine, oedema was
markedly extended to the anterior aspect of the tail. Palpable
swellings were rarely detectable before day 7 but in most cases be-
came evident by day 14 post inoculation and regressed by day 21.
In some animals, no obvious swelling appeared at the site of the
vaccination. In the control group, swellings (probably attributable
to trauma) were detected only for the ﬁrst two days post
vaccination.
In the analysis of variance, a comparison of the mean circumfer-
ence for the vaccinated animals (4.66 ± 0.057 and 4.26 ± 0.059 for
the standard and the modiﬁed vaccines, respectively) with that
of the controls (3.35 ± 0.027) indicated that the vaccinates had sig-
niﬁcantly more swelling than the controls (p < 0.001). A compari-
son between the means for the vaccinated groups indicated that
swellings in the standard group were greater than those in the
modiﬁed group (p < 0.001). Rectal temperatures for all the animals
remained within the normal range during the 30 days of post vac-
cination observation, suggesting that no serious infection was
present (data not shown).3.2. Post challenge clinical signs
Clinical responses following challenge at both 3 and 16 months
post vaccination were typical of CBPP and included nasal discharge,
cough, fever, labored breathing, disinclination to move and adop-
tion of postures suggestive of oxygen deﬁciency. Animals with fe-
ver (temperature between 39.5 and 40.6 C) also had anorexia.
Fourteen of 44 animals challenged after 3 months showed fever,
with the earliest raise in temperature observed on day seven post
inoculation. Out of these, 4 (26.7%) were from the control group, 5/
15 (33.3%) from the group that received the standard vaccine and
5/14 (35.7%) from the group that received modiﬁed vaccine. Fol-
lowing challenge at 16 months post vaccination, 21 of 44 cattle
showed fever, with the earliest raise in temperature recorded on
day four after challenge. Unvaccinated control animals all devel-
oped fever of at least 3 days duration between days 4 and 20 fol-
lowing challenge.3.3. Necropsy and lesion scores
Table 2 summarizes the various descriptors of pathology and
mortality as measured for the two challenge experiments at 3ps, 3 or 16 months after vaccination.
16 months
PBS Standard Modiﬁed PBS
15 15 14 15
4.9 1.3 3 8.5
60% 2% 4% 13%
67% 73% 64% 73%
93% 40% 43% 87%
4.7 ± 1.6 1.9 ± 2.2 2.6 ± 2.4 5.3 ± 1.8
8.3 ± 4.8 3.4 ± 3.3 3.8 ± 4.1 8.9 ± 4.0
53% 33% 53% 27%
31% 100% 100% 87%
– 62% 56% –
plasma as in Hudson and Turner (1963).
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outcome for animals from the two vaccinated groups.
The number of animals requiring euthanasia on humane
grounds before the end of each challenge experiment was highest
for the non-vaccinated control group: 9/15 animals for the
3 month challenge (compared to 3/15 for both standard and mod-
iﬁed vaccines) and 13/15 animals for the 16 month challenge
(compared to 2/15 for standard vaccine and 4/15 for the modiﬁed
vaccine).
Isolation of MmmSC was also about half as frequent in vacci-
nated cattle as in the non-vaccinated group for the 3 month chal-
lenge (3/15 and 5/14 compared to 9/15, respectively). This was
not the case for the 16 month challenge, where numbers were
equally high in the three groups (Table 2).
Post-mortem examination revealed gross pathological lesions
characteristic of CBPP including consolidation of the lung paren-
chyma and pleuritis, and well-developed sequestra that were
either unilateral or bilateral. In some cases the pleural cavity con-
tained copious amounts (up to 5 l) of clear amber-colored ﬂuid
with ﬁbrinous ﬂecks. Fibrous adhesions of the parietal and visceral
pleurae were also observed. Lung consolidation was accompanied
by the hepatization and marbling appearance characteristic of
CBPP.
The occurrence of lung lesions was twice as frequent in the non-
vaccinated animals of both challenge groups. Average scores for le-
sion size (see Section 2.6) were also higher in non-vaccinated ani-
mals (Fig. 1 and Table 2).
Composite pathology scores were derived as described by Hud-
son and Turner (1963), on the basis of lesion occurrence, lesion size
and isolation of MmmSC from tissues. Mean scores for non-vacci-
nated groups were higher than those for vaccinated groups in both
3 and 16 month challenges. However, no signiﬁcant difference was
apparent between the two vaccinated groups in each case.3.4. Serology post vaccination and before challenge
Serological responses to vaccination were measured by CFT and
cELISA tests and are summarized in Table 2. Following vaccination,
seroconversion by CFT was observed in 19/30 (63.3%) and 5/30
(16.7%) animals receiving the standard and the modiﬁed vaccines,
respectively. Seroconversion by cELISA was observed in 5/30
(16.7%) and 4/29 (13.8%) of animals for the standard and modiﬁed
groups, respectively. Seroconversion was ﬁrst detected two weeks
post vaccination, and cattle immunized with the standard vaccineFig. 1. Lesion scores of individual cattle, calculated as a combination of lesion size
and tissue isolation, challenged 3 or 16 months post vaccination (means repre-
sented by horizontal bars). Animals that received the standard vaccine (red dots),
modiﬁed vaccine (cyan diamonds) or no vaccine (blue triangles). (For interpretation
of the references to colour in this ﬁgure legend, the reader is referred to the web
version of this article.).seroconverted on average one week earlier than those receiving
the modiﬁed formulation. As expected, seroconversion was not ob-
served in the control group with either test up to 3 months post
vaccination, the time of the ﬁrst challenge. Comparison of cELISA
antibody titres derived from animals vaccinated with the standard
and modiﬁed vaccines with those of control animals conﬁrmed
that there was indeed a response in the vaccinates (v2 = 5.62,
p = 0.06 with 2 df)), but no difference was apparent between the
animals vaccinated with the standard or modiﬁed vaccines
(v2 = 0.00, p = 1.000 with 1 df).
Challenge at 3 months post vaccination was carried out using
half of the animals in each group. Those that remained to be chal-
lenged 16 months after vaccination were followed for seroconver-
sion, observed by cELISA but not by CFT. Using a cut-off point of
55%, we found amongst the samples collected between 3 and
16 months post vaccination 63 positives out of a total of 403 sam-
ples in group 4 (standard vaccine), 41/404 in group 5 (modiﬁed
vaccine) and only four false positives out of 387 samples in the
non-vaccinated group 6, suggesting that the vaccinated groups
had higher titres overall. However, no correlation could be found
between the lesion scores after challenge and the cELISA titres be-
fore challenge, whether we used the mean cELISA titre over the
whole 16 month period, the mean of the four samples from the
month just before challenge, or the differences between the post-
and pre-vaccination titres.
Analysis of the CFT antibody titres showed a statistically signif-
icant difference between vaccinated animals and control animals
(v2 = 33.07, p < 0.001 with 2 df). Within the vaccinated groups,
the group that received the standard vaccine showed signiﬁcantly
higher (v2 = 13.61, p < 0.001 with 1 df) titres than the group that
received the modiﬁed vaccine.
3.5. Serology post-challenge
At 3 months post vaccination, seroconversion by CFT after chal-
lenge was observed in 21/44 cattle (Tables 2 and 3) (8/15 cattle
vaccinated with standard vaccine, 5/14 with modiﬁed vaccine
and 8/15 controls). Seroconversion by cELISA was observed in 24/
44 cattle.
At 16 months post vaccination, seroconversion by CFT after
challenge was observed in 20/44 cattle (Tables 2 and 3) comprising
5 out of 15 vaccinated with the standard vaccine, 8/14 with the
modiﬁed vaccine and seven out of 15 controls. CFT titres ranged
from 1/10 to 1/320. Almost all infected animals became sero-posi-
tive by cELISA after challenge.
3.6. Vaccine efﬁcacy
Protection rate for the two vaccines, calculated using the aver-
age Hudson scores, are outlined in Table 2. After challenge at
3 months post vaccination, the protection rates for the standard
and the modiﬁed vaccine were 77.1% and 51.8%, respectively. Sim-
ilarly, following challenge at 16 months post vaccination, the rates
of the conventional and the modiﬁed vaccines were 61.8% and
56.1%, respectively.
Comparative analysis of vaccinates and the controls showed
that pathology was signiﬁcantly reduced (p < 0.001) in vaccinated
groups. However, the proportion of protected animals was not sig-
niﬁcantly different (p > 0.05) between the group vaccinated with
the standard vaccine and that given the modiﬁed vaccine.4. Discussion and conclusion
Our underlying hypothesis was that buffering the vaccine might
improve the viability of MmmSC and therefore allow larger num-
Table 3
Serology of animals after vaccination and after challenge.
CFTa c-ELISAb
No vaccine Modiﬁed Standard No vaccine Modiﬁed Standard
Post vaccination
% +ve animals seroconverted 0% 17% 63% 0% 14% 17%
% +ve samplesc between 3 and 16 months 0.53% 0% 0.74% 1.03% 9.4% 15%
3 month challenge
% +ve animals after challenge 53% 36% 53% 31% 46% 64%
16 month challenge
% +ve animals after challenge 50% 53% 33% 100% 100% 87%
a Complement ﬁxation test.
b Competitive ELISA (Le Goff and Thiaucourt, 1998).
c Each animal was tested on 29 occasions between 3 and 16 months after vaccination (see Section 2 for details).
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mune responses. However, this was also expected to increase the
possibility of post-vaccinal reactions at the site of inoculation.
Temperature and tail-tip circumferences were therefore moni-
tored. Reactions to both vaccines were similar and in line with
observations from previous vaccination trials with the standard
vaccine (Thiaucourt et al., 2000; Wesonga and Thiaucourt, 2000;
Yaya et al., 1999). Rectal temperatures for all the animals remained
within the normal range (no fever) during the 30 days post vacci-
nation. However, analysis of variance of tail-tip circumferences be-
tween the animals vaccinated with the standard vaccine, the
modiﬁed vaccine, and the PBS control animals indicated inﬂamma-
tion in vaccinates. A comparison indicated that the means for vac-
cinates were signiﬁcantly higher than those of the controls
(p < 0.001). Post-vaccinal reactions observed in this study were less
severe than those reported in a previous study (Wesonga and
Thiaucourt, 2000), where at least 1/40 cattle vaccinated with the
T1/44 strain of MmmSC developed a severe reaction necessitating
destruction. This might reﬂect the fact that vaccination in that trial
was carried out on the neck and not at the tail.
Seroconversion was observed during the 2 months after vacci-
nation by both CFT and cELISA. However, throughout the
16 months of observation, the cELISA test returned signiﬁcantly
higher average titres in the vaccinated groups, particularly in the
ﬁrst two months. Serum titres measured by cELISA varied consid-
erably between animals and between time of sampling, making
identiﬁcation of vaccinated animals only possible if numerous
samples could be analyzed and compared with those from non-
vaccinated animals. Since no correlation could be found between
antibody levels and pathology (lesion score), it remains in question
whether antibodies measured in cELISA are associated with protec-
tion. Although titrations for CFT antibodies were carried out, the
trial protocol did not allow the animals to reach the end point of
the disease progression.
A number of parameters conﬁrmed that the vaccinated groups
were protected, but little difference was apparent between the
two vaccine preparations. In the non-vaccinated groups, more ani-
mals had fever, and three times as many were euthanized before
the end of the experiment because of severe pathology, twice as
many had lung lesions and more yielded MmmSC from tissue (Ta-
ble 2). Lesions of CBPP were similar to those observed in other
studies, but were on average smaller in the two vaccinated groups
than in the non-vaccinated group. However, no statistically signif-
icant differences were found between the groups vaccinated with
the different vaccine preparations for any measured parameter.
Although the study indicated that the standard vaccine offers a
better protection (77%) than the modiﬁed vaccine (52%) after
3 months, the difference was not statistically signiﬁcant
(p > 0.05). The protection rates after 16 months were also very sim-
ilar (62% and 56%). This demonstrates that the protection offeredby the live vaccine preparations is still present more than one year
after vaccination, which is longer than was generally accepted
(Windsor et al., 1972; Gilbert et al., 1970; Masiga et al., 1978., We-
songa and Thiaucourt, 2000). However, this was a limited study
carried out under optimal conditions. Variables that might affect
vaccine efﬁcacy include MmmSC viability and quantity in the vac-
cine preparation, the condition of the animals (stress and other dis-
eases) when vaccinated, and the conditions under which the
vaccine must be administered.
The protection rates achieved in this experiment (between 52%
and 77%) are comparable to those observed in previous studies and
are in agreement with the statistical estimates of T144 vaccine efﬁ-
ciency (Mariner et al., 2006a,b) of 50–80%. Trials carried out earlier
(Thiaucourt et al., 2000; Yaya et al.,1999) established that a single
vaccination conferred between 30% and 60% protection while a
second boosting vaccination raises protection levels to 80–90%
(Wesonga and Thiaucourt, 2000), suggesting that levels of protec-
tion consistent with control of the disease could be achieved with a
second vaccination.
Despite observations in vitro (March, 2004), incorporation of a
buffer in the culture medium did not improve efﬁcacy of the vac-
cine in this clinical trial. In laboratory conditions, the time span be-
tween reconstitution and administration of the vaccine is relatively
short, while in ﬁeld conditions this is not necessarily the case. It is
then also expected that the beneﬁts of the buffered vaccine will be
more visible in the ﬁeld when less optimum conditions for preser-
vation of viability are present. Large-scale ﬁeld studies have been
carried out in a CBPP-endemic area in Kenya to address this ques-
tion (manuscript in preparation).
Our data suggest that improving the quality of viable organisms
does not improve the efﬁcacy of the vaccine under the conditions
described. In previous studies, evaluation of the T1/44 or T1sr vac-
cines across a range of doses did not reveal a dose–response effect
(Thiaucourt et al., 2000). Considering our data, this suggests that as
long as a sufﬁcient number of viable organisms are administered
that have the potential to multiply, enough antigen will be present
to induce an immune response.
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